Loading...
•
Jun 30, 2025
MannKind Q2 2025 Earnings Report
MannKind reported its second quarter 2025 financial results, highlighting increased revenues driven by royalties and Afrezza sales, alongside progress in its pipeline programs.
Key Takeaways
MannKind Corporation delivered a strong second quarter in 2025, with total revenues increasing by 6% year-over-year to $76.5 million. The company achieved net income of $0.7 million, a significant improvement from a net loss in the prior year, and reported non-GAAP net income of $13.9 million. Key drivers included higher royalties from Tyvaso DPI and increased Afrezza sales due to higher demand and price. The company also made significant progress in its pipeline, submitting an sBLA for Afrezza in pediatric patients and advancing its MNKD-101 and MNKD-201 programs.
Total revenues for Q2 2025 reached $76.5 million, marking a 6% increase compared to Q2 2024.
The company reported a net income of $0.7 million for Q2 2025, a positive shift from a net loss of $2.0 million in Q2 2024.
Afrezza sales increased by 13% to $18.3 million in Q2 2025, driven by higher demand and price.
MannKind submitted a supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population, with a review acceptance decision expected in early Q4 2025.
Revenue by Segment
Forward Guidance
MannKind Corporation provided an optimistic outlook for its pipeline programs and regulatory milestones, focusing on advancing its inhaled therapeutic products.
Positive Outlook
- Submitted sBLA for Afrezza in pediatric population, with review acceptance expected in early Q4 2025.
- Enrollment for the MNKD-101 (inhaled clofazimine) Phase 3 global clinical trial (ICoN-1) is ahead of schedule, with interim enrollment target expected in early Q4 2025.
- Plan to initiate Phase 2 clinical trial for MNKD-201 (nintedanib DPI) for IPF by year-end 2025.
- Application submitted to FDA to update Afrezza labeling regarding initial conversion dose, with a decision expected in Q4 2025.
- Majority of revenue and future pipeline programs are derived from U.S.-based manufacturing, mitigating potential tariff exposure.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...